Published in J Am Soc Nephrol on April 09, 2008
Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes. Int J Endocrinol Metab (2012) 1.90
Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease. Kidney Int (2016) 1.51
Low bone mineral density and fractures in stages 3-5 CKD: an updated systematic review and meta-analysis. Osteoporos Int (2014) 1.03
Current and future treatment options in osteoporosis. Eur J Clin Pharmacol (2011) 0.98
Bone mineral density by DXA and HR pQCT can discriminate fracture status in men and women with stages 3 to 5 chronic kidney disease. Osteoporos Int (2012) 0.98
Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res (2015) 0.95
Diagnosis and management of osteoporosis in the older senior. Clin Interv Aging (2009) 0.90
The effects of raloxifene on bone turnover markers and bone mineral density in women on maintenance hemodialysis. Clin Exp Nephrol (2010) 0.83
Updated recommendations for the diagnosis and management of osteoporosis: a local perspective. Ann Saudi Med (2011) 0.81
Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update. Int J Womens Health (2010) 0.79
Treatment of osteoporosis in renal insufficiency. Clin Rheumatol (2015) 0.76
Effects of raloxifene on bone metabolism in hemodialysis patients. Int J Endocrinol Metab (2012) 0.75
Raloxifene in hemodialysis patients. Int J Endocrinol Metab (2012) 0.75
Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease. Biomed Res Int (2017) 0.75
Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. J Nephrol (2017) 0.75
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med (1995) 10.99
Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int (2005) 10.42
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol (2005) 5.99
Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab (2004) 3.59
Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med (2007) 3.27
Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index. Am J Kidney Dis (2005) 3.14
Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. J Bone Miner Res (1996) 2.46
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98
Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol (2006) 1.92
Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol (2006) 1.91
Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res (2007) 1.88
Vascular calcification in chronic kidney disease. Am J Kidney Dis (2004) 1.81
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) (2000) 1.59
The aetiology of senile osteoporosis: secondary hyperparathyroidism due to renal failure. Q J Med (1975) 1.55
Relationship of gender, age, and body mass index to errors in predicted kidney function. Nephrol Dial Transplant (2005) 1.52
Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab (1988) 1.46
Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res (2005) 1.42
Measures of renal function, BMD, bone loss, and osteoporotic fracture in older adults: the Rancho Bernardo study. J Bone Miner Res (2007) 1.31
Osteoporosis in chronic kidney disease. Am J Kidney Dis (2004) 1.29
Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int (2006) 1.29
Kidney function predicts the rate of bone loss in older individuals: the Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci (2006) 1.20
Estimation of glomerular filtration rate in older patients with chronic renal insufficiency: is the modification of diet in renal disease formula an improvement? J Am Geriatr Soc (2003) 1.19
Osteoporosis in end-state renal disease. Semin Nephrol (1999) 1.14
Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int (2003) 1.10
Biochemical parameters associated with low bone density in healthy men and women. J Bone Miner Res (1992) 0.99
Dual X-ray absorptiometry quality control: comparison of visual examination and process-control charts. J Bone Miner Res (1996) 0.93
Effect of declining renal function on bone density in aging women. Calcif Tissue Int (1988) 0.89
Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep (2005) 0.86
Bone mass is related to creatinine clearance in normal elderly women. J Bone Miner Res (1991) 0.84
Comparative calibration without a gold standard. Stat Med (1997) 0.84
Bone mass status in different degrees of chronic renal failure. Bone (1992) 0.83
Renal disease in the elderly. Nephron (1998) 0.79
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Ultrasonography versus computed tomography for suspected nephrolithiasis. N Engl J Med (2014) 11.30
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med (2003) 7.25
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet (2009) 6.66
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med (2012) 5.81
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med (2008) 5.14
High-trauma fractures and low bone mineral density in older women and men. JAMA (2007) 5.00
Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA (2011) 4.83
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med (2008) 4.81
BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res (2003) 4.64
Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med (2011) 4.28
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 4.09
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med (2005) 4.03
Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med (2007) 3.50
A comparison of prediction models for fractures in older women: is more better? Arch Intern Med (2009) 3.37
Bone mineral density and the risk of incident nonspinal fractures in black and white women. JAMA (2005) 3.30
Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med (2007) 3.27
The magnitude of acute serum creatinine increase after cardiac surgery and the risk of chronic kidney disease, progression of kidney disease, and death. Arch Intern Med (2011) 3.17
Frailty in older men: prevalence, progression, and relationship with mortality. J Am Geriatr Soc (2007) 3.15
Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab (2006) 3.15
Long-term risk of incident vertebral fractures. JAMA (2007) 3.15
Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J Am Soc Nephrol (2005) 3.14
A comparison of frailty indexes for the prediction of falls, disability, fractures, and mortality in older men. J Am Geriatr Soc (2009) 3.09
Fetuin-A and incident diabetes mellitus in older persons. JAMA (2008) 2.92
Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell (2009) 2.79
Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care (2002) 2.72
Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA (2011) 2.70
Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med (2008) 2.66
Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA (2003) 2.62
Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA (2007) 2.62
Informed Consent. N Engl J Med (2017) 2.56
Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol (2005) 2.55
Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat (2005) 2.53
Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res (2005) 2.49
Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann Neurol (2011) 2.46
Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med (2008) 2.44
Relationship of changes in physical activity and mortality among older women. JAMA (2003) 2.42
Population structure, admixture, and aging-related phenotypes in African American adults: the Cardiovascular Health Study. Am J Hum Genet (2005) 2.41
Hip fracture in women without osteoporosis. J Clin Endocrinol Metab (2005) 2.35
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res (2012) 2.34
Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc (2011) 2.34
Central nervous system active medications and risk for fractures in older women. Arch Intern Med (2003) 2.30
Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res (2010) 2.29
Reduced renal function and sleep-disordered breathing in community-dwelling elderly men. Sleep Med (2008) 2.26
The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol (2012) 2.24
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer (2011) 2.20
Prediction of incident hip fracture risk by femur geometry variables measured by hip structural analysis in the study of osteoporotic fractures. J Bone Miner Res (2008) 2.18
Volume of mammographic density and risk of breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 2.18
Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med (2007) 2.17
Diabetes and incidence of functional disability in older women. Diabetes Care (2002) 2.16
Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum (2005) 2.16
Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med (2007) 2.10
Do muscle mass, muscle density, strength, and physical function similarly influence risk of hospitalization in older adults? J Am Geriatr Soc (2009) 2.04
Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA (2011) 2.04
Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial. J Gerontol A Biol Sci Med Sci (2009) 2.01
Alendronate and atrial fibrillation. N Engl J Med (2007) 2.00
The genetics of human longevity. Am J Med (2004) 1.97
Circulating 25-hydroxyvitamin D levels and frailty status in older women. J Clin Endocrinol Metab (2010) 1.93
Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res (2007) 1.93
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res (2012) 1.92
BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res (2006) 1.91
Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res (2007) 1.88
Vision impairment and combined vision and hearing impairment predict cognitive and functional decline in older women. J Am Geriatr Soc (2004) 1.88
Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem (2009) 1.85
Factors associated with kyphosis progression in older women: 15 years' experience in the study of osteoporotic fractures. J Bone Miner Res (2013) 1.84
Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc (2004) 1.84
Poor sleep is associated with poorer physical performance and greater functional limitations in older women. Sleep (2007) 1.82
Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med (2005) 1.81
Low bone mineral density and fracture burden in postmenopausal women. CMAJ (2007) 1.81
Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res (2007) 1.79
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst (2010) 1.79
Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? N Engl J Med (2012) 1.79
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res (2012) 1.78
What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res (2005) 1.76
Comparison of methods to measure low serum estradiol levels in postmenopausal women. J Clin Endocrinol Metab (2006) 1.76
Prevalence and correlates of periodic limb movements in older women. J Clin Sleep Med (2006) 1.76
Finite element analysis of the proximal femur and hip fracture risk in older men. J Bone Miner Res (2009) 1.73
Effective initiation of osteoporosis diagnosis and treatment for patients with a fragility fracture in an orthopaedic environment. J Bone Joint Surg Am (2006) 1.72